表面增强激光解析离子化飞行时间质谱技术筛选肺腺癌血清肿瘤标记物

The study of lung adenocarcinoma serum biomarkers selected by surface-enhanced laser desorption ionization spectrometry

背景与目的:肺癌是目前世界上最常见的恶性肿瘤,由于大多数患者确诊时疾病已属进展期,总体5年生存率较低,所以改善预后的关键在于早期诊断。表面增强激光解析离子化飞行时间质谱技术(SELD I-TOF-MS)是一种检测肿瘤标志物的新兴技术。本研究使用该技术筛选了肺腺癌患者血清相对特异标记物。方法:肺腺癌患者71例,均经手术病理证实;正常人71名,按照性别,年龄,吸烟史与71例肺腺癌患者配对。用WCX2芯片检测各血清标本,筛选肺腺癌相对特异性蛋白质峰。结果:与正常人比较发现肺腺癌显著高表达的潜在标记物5个,相对分子量分别为4047.79±1.60、4203.99±1.91、4959.81±2.13、5329.30±2.55和7760.12±4.11,以峰值比1.5为界值时,其诊断肺腺癌的敏感性分别为90.14%、78.87%、50.70%、57.75%、73.24%,特异性分别为97.18%、92.96%、70.42%、76.06%、94.37%。结论:SELD I-TOF-MS蛋白质质谱技术是一种快速、简便易行且高通量的分析方法,不仅能直接筛选出肺腺癌患者血清中相对特异的潜在标记物,而且可能具有较好的临床应用前景。

Background and Objective： Lung adenocarcinoma is, at present, the most common malignancy in the world and its overall 5 - year survival rate is disappointing. Because most of the patients are diagnosed at advanced stage, early diagnosis may improve the prognosis of patients with lung adenocarcinoma. Surface - Enhanced Laser Desorption and Ionization Mass Spectrometry （SELDI） is one of the currently used techniques to identify biomarkers for cancers. This study explored the application of serum SELDI proteomic patterns to distinguish lung adenocarcinoma patients from healthy individuals. Methods： Serum samples from 71 lung adenocarcinoma patients, 71 healthy volunteers with matched gender, age and history of smoking were analyzed using WCX2 ProteinChip to select potential biomarkers. Proteomic spectra were generated by mass spectrometry. Results： Five highly expressed potential biomarkers were identified with the relative molecular weights of 4047.79±1.60, 4203.99±1.91, 4959.81 ±2.13, 5329.30±2.55 and 7760.12 ±4. 11. The sensitivity for diagnosing lung adenocarcinoma was 90. 14%, 78.87%, 50.70%, 57.75%, 73.24%; and specificity was 97. 18%, 92.96%, 70.42%, 76.06%, 94.37%, when the critical point was made 1.5. Conclusions： SELDI-TOF-MS ProteinChip technology is a quick, easy, convenient, and highoutput analyzing method that it is capable of selecting several relatively specific, potential biomarkers from the serum of lung adenocarcinoma patients and may have clinic value.